A Long Term Follow-up Registry Study of Subjects Who Did Not Achieve Sustained Virologic Response in Gilead-Sponsored Trials in Subjects With Chronic Hepatitis C Infection.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 25 May 2017
At a glance
- Drugs Antivirals (Primary) ; Ledipasvir (Primary) ; Peginterferon alfa-2a (Primary) ; Ribavirin (Primary) ; Sofosbuvir (Primary) ; Tegobuvir (Primary) ; Vedroprevir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Gilead Sciences
- 13 May 2017 Planned End Date changed from 1 Oct 2020 to 1 Jan 2020.
- 13 May 2017 Planned primary completion date changed from 1 Oct 2020 to 1 Jan 2020.
- 13 May 2017 Status changed from recruiting to active, no longer recruiting.